In summary, all these observations in our experimental mouse system provide direct experimental evidence demonstrating the critical requirement of SOS1 function for the development/pathogenesis of CML in mice, thus validating the consideration of SOS GEFs as potential therapeutic targets for the treatment of this disease in human patients. The gene discussed is SOS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.